Identification

Summary

Technetium Tc-99m pyrophosphate is a radiopharmaceutical diagnostic agent used for diagnostic imaging scans for the bones, heart, and gastrointestinal tract.

Generic Name
Technetium Tc-99m pyrophosphate
DrugBank Accession Number
DB09165
Background

A radionuclide imaging agent used primarily in scintigraphy or tomography of the heart to evaluate the extent of the necrotic myocardial process. It has also been used in noninvasive tests for the distribution of organ involvement in different types of amyloidosis and for the evaluation of muscle necrosis in the extremities.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 272.847
Monoisotopic: 272.81818089
Chemical Formula
O7P2Tc
Synonyms
  • Technetium (99mTc) pyrophosphate
  • Technetium TC 99M Pyrophosphate

Pharmacology

Indication

For use as a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction Label. May also be used to image gated blood pools and detect gastrointetinal bleeding.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Technetium Tc-99m pyrophosphate collects in areas of altered osteogenesis and injured myocardium. It also has an affinity for red blood cells, enabling imaging of blood pools.

Mechanism of action

It is thought that technetium Tc-99m pyrophosphate is adsorbed onto the surface of amorphous calcium phosphate deposits 1, insoluble hydroxyapatite crystals, and possibly other organic macromolecules. This would result in selective localization to necrotic muscle tissue such as that of a myocardial infarction where calcium deposition has begun as a result of cell damage. In areas of altered osteogenesis where hydroxyapatite formation is actively occuring, the surface area to volume ratio is high and favors a greater amount of technetium Tc-99m pyrophosphate to the surface of the crystals than in other areas of bone where crystal formation is less active. The localization of technetium Tc-99m pyrophosphate to these areas allows for their specific radioimaging.

TargetActionsOrganism
NHydroxyapatite
ligand
Humans
NAmorphous calcium phosphate
ligand
Humans
Absorption

1-2h after injection approximately 40-50% is localized to the skeleton and 0.01-0.02% per gram to acutely infarcted myocardium Label.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Approximately 40% of the dose is excreted in the urine within 24h Label.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Adverse reactions such as flushing, hypotension, fever, chills, nausea, vomiting and dizziness, as well as hypersensitivity reactions such as itching and various skin rashes have been noted Label. Technetium Tc-99m pyrophosphate is a radiopharmaceutical and carries the risk of radiation toxicity if inappropriately dosed.

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
AceclofenacAceclofenac may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
AcemetacinAcemetacin may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
AcetaminophenAcetaminophen may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
AcetazolamideAcetazolamide may increase the excretion rate of Technetium Tc-99m pyrophosphate which could result in a lower serum level and potentially a reduction in efficacy.
Acetylsalicylic acidAcetylsalicylic acid may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
AclidiniumAclidinium may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
AcrivastineTechnetium Tc-99m pyrophosphate may decrease the excretion rate of Acrivastine which could result in a higher serum level.
AcyclovirAcyclovir may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Adefovir dipivoxilAdefovir dipivoxil may decrease the excretion rate of Technetium Tc-99m pyrophosphate which could result in a higher serum level.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Kit for the Preparation of Technetium Tc99m PyrophosphateInjection12 mg/10mLIntravenousSun Pharmaceutical Industries, Inc.1987-06-30Not applicableUS flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
Technescan PYPTechnetium Tc-99m pyrophosphate (11.9 mg/10mL) + Stannous chloride dihydrate (3.2 mg/10mL)Injection, powder, lyophilized, for solutionIntravenousMallinckrodt2009-03-202017-07-01US flag

Categories

ATC Codes
V09BA03 — Technetium (99mtc) pyrophosphate
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of inorganic compounds known as transition metal pyrophosphates. These are inorganic compounds in which the largest oxoanion is pyrophosphate, and in which the heaviest atom not in an oxoanion is a transition metal.
Kingdom
Inorganic compounds
Super Class
Mixed metal/non-metal compounds
Class
Transition metal oxoanionic compounds
Sub Class
Transition metal pyrophosphates
Direct Parent
Transition metal pyrophosphates
Alternative Parents
Inorganic salts / Inorganic oxides
Substituents
Inorganic oxide / Inorganic salt / Transition metal pyrophosphate
Molecular Framework
Not Available
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
5L76I61H2B
CAS number
52997-54-3
InChI Key
OOGKGVXDDGJCPO-NLQOEHMXSA-J
InChI
InChI=1S/H4O7P2.Tc/c1-8(2,3)7-9(4,5)6;/h(H2,1,2,3)(H2,4,5,6);/q;+4/p-4/i;1+2
IUPAC Name
(99Tc)technetium(4+) ion (phosphonooxy)phosphonate
SMILES
[99Tc+4].[O-]P([O-])(=O)OP([O-])([O-])=O

References

General References
  1. Buja LM, Tofe AJ, Kulkarni PV, Mukherjee A, Parkey RW, Francis MD, Bonte FJ, Willerson JT: Sites and mechanisms of localization of technetium-99m phosphorus radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest. 1977 Sep;60(3):724-40. [Article]
PubChem Compound
6452753
PubChem Substance
347827829
RxNav
1488368
FDA label
Download (104 KB)
MSDS
Download (28.3 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntravenous12 mg/10mL
Injection, powder, lyophilized, for solutionIntravenous
Kit
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilitySolubleMSDS
Radioactivity (mCi/mL)2FDA Label
Predicted Properties
PropertyValueSource
Water Solubility10.8 mg/mLALOGPS
logP1.43ALOGPS
logP-1.4ChemAxon
logS-1.6ALOGPS
pKa (Strongest Acidic)1.7ChemAxon
Physiological Charge-3ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area135.61 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity21.04 m3·mol-1ChemAxon
Polarizability9.03 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Small molecule
Organism
Humans
Pharmacological action
No
Actions
Ligand
References
  1. Buja LM, Tofe AJ, Kulkarni PV, Mukherjee A, Parkey RW, Francis MD, Bonte FJ, Willerson JT: Sites and mechanisms of localization of technetium-99m phosphorus radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest. 1977 Sep;60(3):724-40. [Article]
Kind
Small molecule
Organism
Humans
Pharmacological action
No
Actions
Ligand
References
  1. Buja LM, Tofe AJ, Kulkarni PV, Mukherjee A, Parkey RW, Francis MD, Bonte FJ, Willerson JT: Sites and mechanisms of localization of technetium-99m phosphorus radiopharmaceuticals in acute myocardial infarcts and other tissues. J Clin Invest. 1977 Sep;60(3):724-40. [Article]

Drug created at October 05, 2015 17:05 / Updated at October 09, 2021 02:48